TARS: צמיחת רווחי EPS רבעונית Tarsus Pharmaceuticals, Inc.
The reliability of Tarsus Pharmaceuticals (TARS) is based on the management of regulatory risks and a focused portfolio of ophthalmological products. The quarterly EPS growth rate on GURU.Markets reflects the precise execution of the strategy, where the value is maintained at -4768.20. High patent barriers protect developments, while the rapid market penetration of the blepharitis drug confirms the colossal demand for innovative therapy.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%9E%D7%95%D7%A0%D7%97%D7%99%D7%9D%20%D7%A9%D7%A0%D7%AA%D7%99%D7%99%D7%9D%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_TARS_-_Tarsus-Pharmaceuticals_-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "Tarsus Pharmaceuticals, Inc. (TARS): צמיחת רווחי EPS רבעונית מ-04.07.2022 עד 14.11.2026 | 👁️GURU.Markets👁️")
פילוחי נתונים אנליטיים מרוכזים עבור Tarsus Corp (TARS)
This metric is calculated as the percentage deviation of current earnings per share from the value of the same period last year. This metric measures the efficiency of generating net income available to shareholders after all operating expenses. For Tarsus Pharmaceuticals (TARS), this rate reflects the commercial success of sales for its ophthalmologic drug against blepharitis. Analyzing the quarterly EPS change allows for the identification of a systemic slowdown in profitability. Stable growth on this chart confirms the quality of capital management.
